Shionogi & Co., Ltd.

This phase 3 trial is testing whether the oral antiviral secutrelvir can prevent severe COVID-19 in people who are at high risk for complications. Participants with mild symptoms and confirmed SARS-CoV-2 infection will receive either secutrelvir or a placebo. The study will measu…

This phase 3 trial is testing whether the oral drug secutrelvir can help people with COVID-19 recover faster. The study involves about 1,200 nonhospitalized participants aged 12 to 75 who start treatment within 48 hours of symptom onset. Half will receive secutrelvir and half a p…

This study tests an experimental antiviral drug called S-337395 in adults with RSV who are at high risk for severe illness. Participants must have symptoms for less than 72 hours and a confirmed RSV infection. The goal is to see if the drug can lower the amount of virus in the bo…

This study tests an experimental oral drug called S-606001 in 45 adults with late-onset Pompe disease. Participants take the drug or a placebo on top of their standard enzyme replacement therapy. The main goal is to see if the drug improves lung function and walking ability over …

This study tests a new drug called S-531011, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapies. The goal is to find safe doses and see if the drug can shrink tumors or slow their growth. About 282 adults with…

This study is testing a medicine called naldemedine to help children who get constipated from taking opioids (strong painkillers). About 24 children with cancer or other pain conditions will receive a single dose of the drug. Researchers will measure how the drug moves through th…